วัน: 11 สิงหาคม 2025

DUBAI, Aug 11, 2025 - (ACN Newswire via SeaPRwire.com) - 31 Concept (31C), an emerging leader in network intelligence and cybersecurity innovation, today announced it will unveil its first patent-pending technology at ISS Asia 2025 in Singapore. The breakthrough, developed entirely within the company's 31 Concept Research Lab, marks a major milestone for the startup, which is stepping out of stealth mode after just seven months of intense development.31 Concept's Innovation PatentedThe 31 Concept Research Lab serves as the company's innovation engine, uniting world-class experts in deep packet inspection, AI-driven analytics, cybersecurity, and advanced networking. With decades of combined experience from projects spanning telecom, military, and national infrastructure, the lab's team operates at the intersection of applied research and practical deployment, delivering solutions designed to solve real-world challenges at scale."Our patent-pending technology is the direct result of the unique expertise and relentless drive inside our Research Lab," said Misha Hanin, CEO and Co-Founder of 31C. "We built this in record time without compromising on quality or innovation. This is just the first step in a series of breakthroughs we intend to bring to the market."ISS Asia, recognized as one of the most important professional conferences in the world for intelligence, security, and law enforcement technologies, will provide the global stage for the debut. The event draws leaders from government, telecom, and private industry, making it the perfect venue for 31C's first public presentation."The speed at which the 31 Concept Research Lab turned a concept into a patent-pending reality shows the strength of our people and our process," added Boriss Heismann, CTO of 31C. "This is technology designed to address the most pressing needs in network visibility, security, and performance - and to do it in ways the industry has not seen before."The company's presentation at ISS Asia 2025 will highlight the capabilities of the new platform, detail the patent-pending elements, and outline the roadmap for further innovations currently in development.About 31C31 Concept is a technology company focused on next-generation data intelligence platforms for telecom providers, governments, and regulated industries. Its flagship R&D division, the 31 Concept Research Lab, develops breakthrough technologies in network intelligence, cybersecurity, and AI-driven analytics.Contact InformationMisha HaninCEOmisha.hanin@31c.ioSOURCE: 31 ConceptRelated Images Copyright 2025 ACN Newswire via SeaPRwire.com.

KUALA LUMPUR, Aug 8, 2025 - (ACN Newswire via SeaPRwire.com) - Qube Integrated Malaysia Sdn. Bhd. (Qube), a leading local business events industry player celebrating its 20th anniversary this year, won 10 prestigious awards at the Malaysia Business Events Awards (MBEA) 2025, organised by the Malaysian Association of Convention and Exhibition Organisers and Suppliers (MACEOS) last night.The company, an established name in the MICE (Meetings, Incentives, Conferences and Exhibitions) industry, was honoured at the event held at the Kuala Lumpur Convention Centre with five Excellence Awards and five Merit Awards, out of the 10 categories it was shortlisted for, including:1. Exhibition Management Excellence Award: Qube for Malaysia International Halal Showcase (MIHAS) 20242. Trade Exhibition Excellence Award for events between 10,001–20,000 sqm: BuildXpo Malaysia 20243. Booth Design Excellence Award for booths below 72sqm held in overseas: MyCEB Pavilion at IMEX Frankfurt4. Booth Design Excellence Award for single deck booth 73 sqm & above: Proton Pavilion at KLIMS 20245. Stage Design Excellence Award: Acer APAC Predator League 20256. Trade Exhibition Excellence Merit Award (20,001 sqm and above): MIHAS 20247. Event Excellence (B2B – Corporate) Merit Award: Proton e.MAS 7 Grand Launch8. Booth Design Excellence Merit Award (Double Deck): Malaysia Airlines @ MATTA Fair – March 20249. Merit Award Booth Design Excellence Merit Award (Double Deck): Malaysia Airlines @ MATTA Fair – Sept 202410. Purpose-Built Venue Excellence Merit Award (15,001 sqm and above): Malaysia International Trade and Exhibition Centre (MITEC)Founded in 2005 and headquartered in Kuala Lumpur, Qube marks its 20th anniversary this year with a bold step forward in digital innovation, talent development, and regional collaboration. Reinforcing its long-term commitment to shaping the future of MICE, the company has announced several new initiatives that underline its role as a strategic player in Malaysia’s trade and tourism growth.Over the last two decades, Qube has grown from a boutique design-and-build agency into a powerhouse for creative and executional excellence in exhibitions and events. The company has delivered Malaysia’s pavilions at global showcases, including Expo 2017 Astana and Expo 2020 Dubai, which drew millions of visitors. In 2024, Qube set a significant milestone when the company acquired the tenure to manage the Malaysia International Trade and Exhibition Centre (MITEC), the country’s largest business events venue.In 2024, Qube also acquired SEA Healthcare & Pharma Show (SEACare), a long-running business trade exhibition in the medical and pharma sector. Most recently, Qube designed, built and managed the Malaysia Pavilion at the 2025 Mobile World Congress in Barcelona, and continues to manage MIHAS, the world’s largest halal trade fair and a Guinness World Records title holder.On this achievement, Richard Teo, Executive Chairman of Qube, said: “This recognition means a great deal to us. It reflects the dedication of our team, the trust of our clients, and the strength of the partnerships we have built. These platforms do more than showcase what we can do. They position Malaysian brands globally, create new opportunities for SMEs, and attract long-term business and investment into the country.”“Business events are not just about putting people in the same room. They help drive innovation, stimulate economic activity, support jobs and strengthen supply chains. At the heart of it all, we are focused on creating meaningful impact for our clients, our people and the nation,” he added.Collaboration with the Public SectorQube continues to work closely with public agencies including MATRADE, the Construction Industry Development Board (CIDB), the Malaysia Convention & Exhibition Bureau (MyCEB) and others. These partnerships align with national priorities under the 13th Malaysia Plan and ongoing tourism recovery efforts, particularly in SME development, export growth, talent upskilling and business event-driven tourism.Looking ahead, Qube will play a central role in several major upcoming platforms:MIHAS 2025, in partnership with MATRADESME Venture@ASEAN 2025, with SME Corporation MalaysiaICW & BuildXpo 2025, co-organised with CIDB MalaysiaIn addition, Qube will host its signature event, WE2025: Future in Motion, a flagship initiative for empowering women in business, leadership, and innovation, from 25 to 27 November 2025. Themed Women in Trade. Investment. Leadership., this multi-platform event is organised in collaboration with the Ministry of Women, Family and Community Development and the Department of Women Development.WE2025 features four integrated pillars: a leadership conference, a large-scale trade and investment expo, curated business matching and key side events.Aimed at women entrepreneurs, corporate leaders, SMEs, startups, youth, ecosystem enablers and inclusive industries from across ASEAN and beyond, WE2025: Future in Motion is expected to attract 10,000 visitors, 1,000 delegates, 500 exhibitor booths, and generate RM100 million in trade and investment opportunities.“We have always believed in using our platforms to make a lasting difference. Whether it is through delivering a high-impact trade show, empowering local brands, or raising the bar in venue management, our purpose has remained the same. Our growth is powered by talent, shaped by innovation, and guided by the values of inclusivity and excellence,” added Teo.Contacts for Media Enquiries:  MNAIR PR Consultancy Sdn. Bhd.Sashikala NairDirector, Public Relations+6012 566 9095sashi@mnairpr.comShuman VasuAssociate Director, Public Relations+6017 354 6461shumanv@mnairpr.comQube Integrated Malaysia Sdn. Bhd. (Qube)Yasmin BathamanathanManager, PR & Communications+6012 358 9063yasmin@qube.com.my Copyright 2025 ACN Newswire via SeaPRwire.com.

TransNusa Increases Flight Options For Two Routes From ManadoPT TransNusa Aviation Mandiri converts two chartered flights from Manado to scheduled commercial flightsTickets sale for Manado to Shanghai and Manado to Shenzhen started on July 29, 2025TransNusa continuously expands international route and starts strengthening Manado base in IndonesiaJAKARTA, Aug 11, 2025 - (ACN Newswire via SeaPRwire.com) - FOCUSING on organic growth, TransNusa converts two charter flight routes between Manado and Shanghai as well as Manado and Shenzhen to scheduled commercial routes, starting 8 September and 2 October, respectively.TransNusa Group Chief Executive Officer, Datuk Bernard Francis said while the Manado-Shenzhen scheduled commercial flight is direct, the Manado-Shanghai flight plan has a stop-over of between 30 to 35 minutes at the Clark International Airport.“Our main priority and focus is to create new exciting routes for our passengers and offer seamless and fast travels, whether through direct routes or transits routes.” Datuk Francis said, explaining that the Manado-Clark-Shenzhen route is very popular among tourists.“With the launch of these new commercial routes, we hope to provide tourists from Manado and China additional options to travel,” Datuk Francis said, adding that TransNusa will also provide its passengers with options to visit other major tourist destinations from Manado, such as Bali, also known as Indonesia’s Island of Gods.Details of the new RoutesFrom October 2, TransNusa will be operating three flights a week from Manado’s Sam Ratulangi International Airport to Shenzhen Bao’an International Airport. The TransNusa flight, 8B 175, will depart Manado at 21.10pm and arrive at the Shenzhen Bao’an International Airport at 01.00am while TransNusa flight, 8B 176, will depart Shenzhen Bao’an International Airport at 02.00am and arrive in Manado at 05.50am.TransNusa will be operating the Manado-Shenzhen route three times weekly. The Manado-Shenzhen route scheduled commercial flights are on Tuesday, Thursday and Saturday while the Shenzhen-Manado route scheduled commercial flights will be on Wednesday, Friday and Sunday.TransNusa’s scheduled Manado-Shenzhen flight ticket price starts from as low as IDR3.499.000, CNY1.525 and USD226 while it’s schedule flight from Manado to Shanghai ticket price starts from as low as IDR3.988.000, CNY1.688 and USD257. TransNusa tickets are available for purchase at transnusa.co.id and all other main online travel agent platforms worldwide.Meanwhile, the TransNusa flight, 8B 101, from Manado will depart at 14.00pm and arrive at the Clark International Airport at 16.40pm. The flight will depart Clark International Airport at 17.15pm and arrive at the Shanghai Pudong International Airport at 20.55pm. The flight, 8B 102, will depart the Shanghai Pudong International Airport at 23.05pm and arrive at Clark International Airport at 02.30am. The TransNusa 8B 102, will depart Clark International Airport at 03.00am and arrive at Manado’s Sam Ratulangi International Airport at 05.30am.Datuk Bernard said that TransNusa will operate the six hours 50 minutes scheduled commercial flight route 3 times week. TransNusa’s scheduled commercial flight from Manado will depart on Monday, Wednesday, and Friday.For both the newly introduced scheduled commercial flights, Datuk Bernard said TransNusa will be utilizing its C909 jet airliner, which has only 95 seats, to ensure that passengers travel with comfort.Datuk Bernard Francis…TransNusa offers new flight options for its passengersBrief History On TransNusaTransNusa, which had to close business due to the Covid-19 pandemic was injected with new shareholders and management team in 2022. The airline opened its doors for business in October and within six months, in April 2023, launched its first international flight from Jakarta to Kuala Lumpur, Malaysia.After which, under the new leadership of Datuk Francis, and the new management team, the airline successfully launched three more new international routes by the end of 2023. In 2024, the airline continued growing its international and domestic route and at the same time recording historical firsts that also became a significant industry first for the Indonesian aviation industry. Since April 2023, TransNusa has been making headlines in Malaysia, Singapore, China and around the world with news of being the first airline in Indonesia and the world to develop and introduce a new domestic route connecting Bali and diving haven, Manado. TransNusa also became the second Indonesian airline to receive approval to fly to China and provided Indonesians with more pricing and route options to China.TransNusa’s aggressive international growth strategy combined with its domestic business operations approach has enabled the airline to be the fastest growing airline in South East Asia.About TransNusaTransNusa Airline, is a Premium Service Carrier. After the take-over, in February 2024, the airline rebranded itself from being a Low-Cost Carrier to a Premium Service Carrier in line with its upgraded aircrafts that offers better comfort as well as based on the flexibility and quality of the services offered.TransNusa, which received its AOC certification on 9th September 2022, launch its first three A320 operations on 6th October, 14th October and 12th December, 2022.  In 2023, TransNusa introduced a new business model making it the first Premium Service Carrier in the Asia Pacific region. TransNusa introduced its first international flight on 14th April, 2023. The airline is currently has bases in Jakarta, Bali and Manado.The airline currently flies from Jakarta to Yogyakarta, Bali, Kuala Lumpur, Malaysia, Subang, Malaysia and Guangzhou, China. It also flies from Bali to Jakarta and Manado. TransNusa will be launching its scheduled Bali to Perth route on March 20th and its Bali to Guangzhou route on April13th. TransNusa made history when it became the second Indonesian airline to fly to China and the first Indonesian airline to launch a Premium Service Carrier business model.Passengers can book their flights on the TransNusa website (www.transnusa.co.id), through authorized travel agents in Singapore, Malaysia and Indonesia, or by contacting the airline's customer service centre at, +62216310888. For the Singaporean market, passengers can contact TransNusa’s General Sales Agent, Chariot Travels Pte Ltd, at +65 86602719 for assistance.TransNusa’s Primary Media Contact:Trina Thomas Rajtrina@myqaseh.org+60124992672 (watsapp) Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 11, 2025 - (ACN Newswire via SeaPRwire.com) - Cryofocus Medtech (Shanghai) Co., Ltd. ("Cryofocus" or the "Company," Stock Code: 6922.HK), a global innovator in minimally invasive interventional cryotherapy, last friday announced its unaudited interim results for the six months ended June 30, 2025. The Company demonstrated robust growth momentum and significant operational optimization during the reporting period, with key financial metrics delivering exceptional performance. Notably, its respiratory intervention product portfolio fueled a substantial revenue surge, marking accelerated commercialization progress.Respiratory Intervention Products Emerge as Core Growth Engine, Highlighting Global Competitive EdgeThe Company recorded revenue of RMB51.1 million for the first half of 2025, a 162.4% increase from RMB19.5 million in the same period of 2024, setting a new historical high. This growth was primarily attributable to the strategic focus on respiratory intervention products entering a harvest phase: The Malignant Stenosis Cryoablation System, approved by China’s National Medical Products Administration (NMPA) in March 2025, and the previously commercialized Cryoadhesion System, experienced rapid sales expansion, becoming the dominant revenue drivers. Additionally, the distribution partnership with Boston Scientific’s China affiliate, BSC International Medical Trading (Shanghai) Co., Ltd. (“BSC”), contributed significant incremental revenue from other respiratory intervention products in mainland China.Of particular significance, the Company’s Asthma Cryoablation System received "Breakthrough Medical Device" designation from the U.S. Food and Drug Administration (FDA) – the first such international recognition for a Chinese enterprise in the respiratory interventional cryotherapy field – laying a foundation for global market expansion.Cryofocus has established a highly competitive respiratory intervention portfolio addressing critical indications, including malignant stenosis, benign stenosis, asthma, chronic obstructive pulmonary disease (COPD), peri-pulmonary nodules, chronic cough, and airway tuberculosis. Among these: The Malignant Stenosis Cryoablation System has been successfully commercialized in China; systems for asthma and COPD are in confirmatory clinical trials with expected approvals in 2026; products for cough, tuberculosis, and peri-pulmonary nodules are in various R&D stages; and the Cryoadhesion System (including disposable and re-sterilizable cryoprobes) is approved and marketed. These innovations mainly stem from Cryofocus’s two core technology platforms: unique liquid nitrogen-based cryoablation technology (utilizing liquid nitrogen as the cryogenic energy source) and advanced flexible catheter technology. This integrated platform enables deep low-temperature treatment, precise control, and minimally invasive intervention, offering superior therapeutic efficacy and safety while creating significant technological barriers for competitors.Platform Value Multiplies as Multi-Segment Strategy Accelerates CommercializationCryofocus’s core value extends beyond its respiratory pipeline, underpinned by its distinction as an innovative cryotherapy platform enterprise. Leveraging its liquid nitrogen and flexible catheter technologies, the Company has successfully expanded into multiple high-potential therapeutic areas:In the vascular intervention segment: The Atrial Fibrillation (AF) Cryoablation System (for atrial fibrillation treatment) was commercialized in China in September 2024. The Cryofocus Renal Denervation (Cryo-RDN) System (for hypertension treatment), granted FDA Breakthrough Device designation, is in confirmatory clinical trials. The Pulmonary Hypertension Cryoablation System is currently in the stage of pre-clinical study. The market space for all these related cardiovascular indications is very huge.In the Natural Orifice Transluminal Endoscopic Surgery (NOTES) segment: The respiratory intervention portfolio, as detailed, is rich and leading. The cancer intervention portfolio includes the commercialized Bladder Cryoablation System; the Gastric Cryoablation System and Esophageal Cryospray System are in clinical trials targeting gastric and esophageal cancer markets.In non-cryotherapy products: Commercialized items such as the Pulmonary Nodule Localization Needle and Endoscopic Clip for Anastomosis, alongside pipeline products like the Atrial Fibrillation Pulsed Field Ablation (PFA) System and Anti-Gastroesophageal Reflux System, create complementary synergies.This "one-platform, multi-therapy" model endows Cryofocus with exceptional adaptability for indication expansion and pipeline sustainability. The Company currently boasts a robust portfolio of 23 products and candidates: 14 cryotherapy and 9 non-cryotherapy items, with 11 already commercialized. Such platform-based diversification is rare among single-therapy medical device firms, highlighting substantial long-term growth potential and risk resilience.Strong Financial Performance and Sustained Growth MomentumBeyond the revenue surge driven by respiratory products, Cryofocus’s interim results signal positive ongoing growth. The Company’s technological advantages further translated into financial resilience. Gross profit reached RMB34.3 million for the first half of 2025, up 124.5% year-on-year, with a solid gross profit margin of 67.1%. Enhanced R&D efficiency led to significantly reduced losses. R&D expenses optimized to RMB17.9 million (down 51.9% year-on-year), while the period loss narrowed 51.4% to RMB27.2 million, demonstrating a clear trend toward profitability. Cash reserves increased 40.1% from year-end 2024 to RMB63.7 million, providing a solid foundation for sustained R&D and market expansion.Revenue diversification and quality improved as high-value self-developed products (e.g., Malignant Stenosis Cryoablation System) launched and scaled, complemented by deepening collaboration with BSC. The significant reduction in R&D expenses reflects improved efficiency and reduced consumable needs as products advance, driven by optimized personnel costs and management enhancements. This establishes a sound framework for balancing innovation intensity with cost control.Furthermore, the Company increased investment in sales network development, with selling and distribution expenses rising 174.4% year-on-year to RMB9.2 million, underscoring proactive resource allocation to build marketing teams and promote newly launched products (e.g., Malignant Stenosis Cryoablation System), laying groundwork for future sales scale expansion.Global Peer Benchmark Highlights Valuation PotentialCryofocus’s technological strength in respiratory interventional cryotherapy, particularly in FDA-designated areas like asthma treatment, positions it competitively against global leaders.Benchmarked against Inspire Medical Systems (INSP) (focusing on OSA neurostimulation, differing in indication but similar in respiratory neuro-intervention): Inspire currently holds a market capitalization of US$2.279 billion and a trailing-twelve-month (TTM) P/E ratio of 44.28x. Cryofocus’s Asthma Cryoablation System similarly targets pulmonary vagal nerves via minimally invasive ablation, with an innovative pathway validated by FDA Breakthrough status. Yet, as a diversified platform innovator with a broad pipeline and multiple commercialized products, Cryofocus’s current Hong Kong market valuation (Inspire’s market cap is 12.8x Cryofocus’s) significantly trails Inspire’s.This substantial valuation gap, while influenced by factors such as differing markets (US vs. HK), stages of development (Inspire being profitable and established in the US market), and a single-product focus versus a platform model, nonetheless clearly underscores the significant upside potential in Cryofocus Medtech's current market valuation relative to its technological capabilities, the breadth of its product pipeline, and its potential for globalization breakthroughs. With the advancement of clinical progress for its respiratory intervention products (particularly the Asthma Cryoablation System COPD Cryospray System Peri-Pulmonary Nodule Cryoablation System), the clarification of overseas registration pathways, and the continued high-speed growth in its revenue scale, a market re-rating of its value represents a high-probability event. The current valuation level presents an attractive window of opportunity for investors bullish on the long-term prospects of the minimally-invasive interventional cryotherapy sector and the value inherent in a platform company model.Looking ahead, Cryofocus maintains a clear strategy: rapidly advance clinical development and commercialization of pipeline products; deepen focus on minimally invasive interventional cryotherapy while expanding the portfolio leveraging its core platforms; continuously invest in underlying and supporting technologies; and selectively expand global operations. The Company is steadily transitioning from R&D-driven to a dual-engine model integrating R&D and commercialization, advancing resolutely toward its vision of becoming a "global platform for minimally invasive interventional cryotherapy medical devices."   Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 11, 2025 - (ACN Newswire via SeaPRwire.com) - On August 8, the first batch of data center REITs—Nanfang Range Technology Data Center REIT and Nanfang Wanguo Data Center REIT—officially debuted on the Shanghai and Shenzhen stock exchanges, both hitting the daily price limit on their first day of trading, closing at RMB 5.850 and RMB 3.9, respectively. Their strong performance marked the official entry of the REITs market into the "tech new infrastructure" arena and underscored the important role of industrial capital in driving the securitization of computing power infrastructure.As a key investor in both projects, Shoucheng Holdings Limited (0697.HK) has once again found itself in the spotlight. Through its wholly-owned subsidiary, Beijing Shouyuan Xinrong Investment Co., Ltd., and the Beijing Pingzhun Infrastructure Real Estate Investment Fund under its management, Shoucheng Holdings invested in both Nanfang Wanguo Data Center REIT and Nanfang Range Technology Data Center REIT. This represents not only another precise move in the data center sector but also the latest step in Shoucheng’s broader REITs market strategy.Tapping into the “Computing Power Base” to Capture Digital Economy GrowthAccording to public information, the Nanfang Wanguo Data Center REIT is backed by the Guojin Data Cloud Computing Center in Huaqiao, Kunshan, with 4,192 racks; the Nanfang Range Technology Data Center REIT is backed by the A-18 Data Center at Runze (Langfang) International Information Port, located in the Beijing-Tianjin-Hebei National Computing Hub, with 5,897 racks and an occupancy rate exceeding 99%. Both assets are core regional computing power resources, playing a vital role in supporting 5G, artificial intelligence, and big data applications.Industry experts note that the launch of data center REITs marks the first time that public REITs in China have covered the technology innovation infrastructure segment, facilitating more efficient allocation of computing resources and enhancing the capital market’s ability to serve the digital economy.Full-Chain Deployment: Building a Closed-Loop REITs EcosystemShoucheng’s involvement in the REITs market has long gone beyond single investments. Since becoming one of the largest strategic investors in China’s inaugural public REITs in 2021, the company has built a complete ecosystem covering “Pre-REITs industrial fund incubation — platform operations — public REITs exit — strategic placement investment.”Currently, Shoucheng’s REITs fund management scale exceeds RMB 30 billion, with investments spanning transportation hubs, urban renewal, green energy, and data centers. In 2025 alone, the company has invested in the Sunlon REIT and the Huadian REIT, and through the Beijing Pingzhun Infrastructure Real Estate Investment Fund, partnered with China Life Investment and Caixin Life Insurance to launch a RMB 10 billion Pingzhun Infrastructure Fund, further strengthening its position as a leading industrial capital player in the REITs market.Industrial Capital Advantage: Driving Sustainable Market DevelopmentAs an industrial capital investor, Shoucheng Holdings not only provides funding but also leverages its expertise in asset management, operations, and integration of intelligent infrastructure to enhance both the operational efficiency and long-term value of underlying assets. This “capital + operations” dual empowerment model differentiates the company from pure financial investors in the REITs market.Analysts believe that with the ongoing expansion of China’s public REITs market and the acceleration of securitization in emerging infrastructure such as data centers, Shoucheng Holdings is well-positioned to benefit from the convergence of “new tech infrastructure + REITs” and to consolidate its leadership in the sector.Posted by All Way Success Company Limited for Shoucheng Holdings www.shouchengholdings.com [HKSE:0697, FRA:SHVA, OTCPK:SHNHF] Copyright 2025 ACN Newswire via SeaPRwire.com.